Vol. 17/No. 6 | Oncology Live®

March 17, 2016

A study involving nearly 30,000 patients diagnosed with early-stage breast cancer has found that up to 60% of these women received imaging tests such as CT, bone, and PET scans that were not medically justified, contrary to national guidelines.

March 16, 2016

The bounty of choices is good news for patients with melanoma, several key questions have emerged: Should immunotherapy or targeted agents be the first-line choice for metastatic melanoma?

March 16, 2016

Robert A. Figlin, MD, FACP, discusses how the genomics of kidney cancer have evolved over recent years.

March 15, 2016

Today, there are multiple choices of regimens in two different modalities that can either prolong survival or allow patients to live without disease progression or recurrence for several years.

March 15, 2016

The antibody–drug conjugate sacituzumab govitecan (IMMU-132) received a breakthrough therapy designation based on phase II trial data showing a response rate of 31% in heavily pretreated patients with metastatic TNBC. However, treatment advances are lagging behind those seen in other breast cancer phenotypes.

March 14, 2016

The Department of Radiation Oncology at Virginia Commonwealth University Massey Cancer Center has long been at the forefront worldwide in the development of various radiation therapy technologies that are now considered standard and have become widely available.

March 14, 2016

Genome sequencing studies are beginning to match distinct genomic profiles to different subtypes of kidney cancer, driving a dramatic shift in our understanding of these diseases and how to treat them.

March 10, 2016

Much work needs to be done to increase Lynch syndrome screening rates and better understand the factors that are associated with low testing rates.

March 10, 2016

The novel therapeutic vaccine algenpantucel-L, which is genetically engineered from human cell lines, is being evaluated in two phase III trials in patients with resected pancreatic cancer (IMPRESS) and borderline resectable or locally advanced unresectable pancreatic cancer (PILLAR).

March 10, 2016

There is growing evidence that continued reliance on the mantra of “randomized phase III trials” is highly problematic.